
Akeso, Inc. — Investor Relations & Filings
Akeso, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs globally. The company integrates comprehensive drug discovery capabilities, including target validation and antibody drug development. Akeso maintains a broad and innovative therapeutic portfolio, primarily concentrated in the fields of oncology and immunology. The company has successfully advanced multiple novel therapies, including five innovative drugs with approved indications, demonstrating its commitment to bringing breakthrough treatments to market. Akeso has notably developed a lung cancer drug that has garnered significant attention within the global biotech sector.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Notification Letter and Reply Form to Non-registered Holders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications | 2026-04-29 | English | |
| Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications | 2026-04-29 | English | |
| 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 2026-04-29 | English | |
| 2025 ANNUAL REPORT | 2026-04-29 | English | |
| ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 2026-03-26 | English | |
| DATE OF BOARD MEETING | 2026-03-16 | English |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AbbVie Inc.
A research-based biopharmaceutical company developing and m…
|
ABBV | US | Manufacturing |
|
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a …
|
ABCL | CA | Manufacturing |
|
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and…
|
174900 | KR | Manufacturing |
|
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapi…
|
ABEO | US | Manufacturing |
|
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering develo…
|
ABDX | GB | Manufacturing |
|
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apoli…
|
ABNX | FR | Manufacturing |
|
ABIVAX
Clinical-stage biotech developing therapeutics for chronic …
|
ABVX | FR | Manufacturing |
|
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for in…
|
ABVX | US | Manufacturing |
|
ABL Diagnostics
Develops molecular diagnostic solutions for managing infect…
|
ABLD | FR | Manufacturing |
|
Abliva
Biopharmaceutical company developing medicines for primary …
|
ABLI | SE | Manufacturing |
Akeso, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/51175/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=51175 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=51175 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=51175 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 51175}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Akeso, Inc. (id: 51175)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.